Comparison of histopathology to gene expression profiling for the diagnosis of metastatic cancer
Open Access
- 21 August 2012
- journal article
- research article
- Published by Springer Nature in Diagnostic Pathology
- Vol. 7 (1) , 110
Abstract
Background: Determining the primary site of metastatic cancer with confidence can be challenging. Pathologists commonly use a battery of immunohistochemical (IHC) stains to determine the primary site. Gene expression profiling (GEP) has found increasing use, particularly in the most difficult cases. In this pilot study, a direct comparison between GEP and IHC-guided methods was performed. Methods: Ten archived formalin-fixed paraffin embedded metastatic tumor samples for which the primary site had been clinically determined were selected. Five pathologists who were blinded to the diagnosis were asked to determine the primary site using IHC and other stains selected from a panel of 84 stains. Each pathologist was provided patient sex, biopsy site and gross sample description only. Slides were digitized using ScanScope®XT at 0.25 μm/pixel. Each evaluating pathologist was allowed to provide a diagnosis in three stages: initial (after reviewing the H&E image), intermediate (after reviewing images from the first batch of stains) and final diagnosis (after the second batch of stains if requested). GEP was performed using the only FDA-cleared test for this intended use, the Pathwork Tissue of Origin Test. No sample information was provided for GEP testing except for patient sex. Results were reported as the tumor tissue type with the highest similarity score. Results: In this feasibility study, GEP determined the correct primary site in 9 of the 10 cases (90%), compared to the IHC-guided method which determined the correct primary site for 32 of 50 case evaluations (average 64%, range 50% to 80%). The five pathologists directing the IHC-guided method ordered an average of 8.8 stains per case (range 1 to 18). GEP required an average of 3 slides per case (range 1 to 4). Conclusions: Results of the pilot study suggest that GEP provides correct primary site identification in a higher percentage of metastatic cases than IHC-guided methods, and uses less tissue. A larger comparative effectiveness study using this study design is needed to confirm the results. Virtual slides: The virtual slide(s) for this article can be found here:http://www.diagnosticpathology.diagnomx.eu/vs/1749854104745508Keywords
This publication has 22 references indexed in Scilit:
- Introduction of virtual microscopy in routine surgical pathology - a hypothesis and personal view from EuropeDiagnostic Pathology, 2012
- Gene expression profiling from formalin-fixed, paraffin-embedded tissue for tumor diagnosisClinica Chimica Acta, 2011
- Validation and Reproducibility of a Microarray-Based Gene Expression Test for Tumor Identification in Formalin-Fixed, Paraffin-Embedded SpecimensThe Journal of Molecular Diagnostics, 2011
- Determining Tissue of Origin for Metastatic CancersApplied Immunohistochemistry & Molecular Morphology, 2010
- Molecular Classification of Cancers of Unknown Primary SiteMolecular Diagnosis & Therapy, 2009
- Multicenter Validation of a 1,550-Gene Expression Profile for Identification of Tumor Tissue of OriginJournal of Clinical Oncology, 2009
- Carcinoma of unknown primary (CUP)Critical Reviews in Oncology/Hematology, 2009
- Diagnostic strategies for unknown primary cancerCancer, 2004
- Cancer from an Unknown Primary SiteThe American Journal of the Medical Sciences, 2003
- Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984–1992European Journal of Cancer, 2002